EDISCIENCES

ABSTRACT

Background: Older adults with colorectal cancer receiving oxaliplatin- based chemotherapy are at high risk for functional decline and chemotherapy- induced peripheral neuropathy (CIPN), which may compromise their independence and quality of life (QOL). Although physiotherapy is recommended to mitigate these adverse effects, participation in structured interventions during chemotherapy is challenging in routine clinical practice. In this study, we aimed to evaluate the feasibility of a home-based physiotherapy intervention and explore changes in physical function and QOL during the study period, with particular attention paid to adherence. Materials and Methods: This 12-week prospective, observational study involved older adults (65 years or older) receiving oxaliplatin-based chemotherapy. Participants were provided with a structured home-based exercise program comprising monthly supervised sessions and individualized self-managed exercises. Outcomes included CIPN, physical function (grip strength, Cancer Functional Assessment Set [cFAS], Purdue Pegboard Test), QOL (Functional Assessment of Cancer Therapy [FACT]–General and FACT/Gynecologic Oncology Group–Neurotoxicity), and activities of daily living (Barthel Index). Sensory thresholds were assessed using the Semmes–Weinstein monofilament test. The analyses were primarily descriptive but with exploratory statistical comparisons. Results: Fourteen participants were enrolled. Twelve patients (median age: 75 years) completed the 3-month intervention and were included in the final analysis. High adherence to both supervised and self-managed exercise sessions was observed. Although the incidence of grade 2 CIPN was 33.3%, no significant deterioration in physical function or QOL was observed during the study period. cFAS scores and grip strength showed a declining trend, whereas bilateral hand dexterity significantly improved (p = 0.045). Conclusions: According to this feasibility study, a home-based physiotherapy approach may be feasible for older patients receiving oxaliplatin-based chemotherapy, and the findings can inform the design of future adequately powered trials.